Marker Therapeutics Inc
NASDAQ:MRKR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marker Therapeutics Inc
NASDAQ:MRKR
|
US |
|
Shanghai Nenghui Technology Co Ltd
SZSE:301046
|
CN |
|
GBM Resources Ltd
ASX:GBZ
|
AU |
|
J
|
Jollibee Foods Corp
XPHS:JFC
|
PH |
|
BGI Inc
OTC:BGRP
|
US |
|
Z
|
Zhejiang Weiming Environment Protection Co Ltd
SSE:603568
|
CN |
|
C
|
China Putian Food Holding Ltd
HKEX:1699
|
CN |
|
VL E-Governance & IT Solutions Ltd
BSE:543958
|
IN |
|
Ecosciences Inc
OTC:ECEZ
|
US |
|
U
|
Unisem Co Ltd
KOSDAQ:036200
|
KR |
|
Westlife Development Ltd
NSE:WESTLIFE
|
IN |
|
A
|
Argo Living Soils Corp
OTC:ARLSF
|
CA |
|
Capstone Copper Corp
TSX:CS
|
CA |
|
Plurilock Security Inc
XTSX:PLUR
|
CA |
|
E
|
Entain PLC
OTC:GMVHF
|
IM |
|
H
|
Hap Seng Plantations Holdings Bhd
KLSE:HSPLANT
|
MY |
Marker Therapeutics Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.
Capital Raise: Marker Therapeutics completed a $56.5 million public offering, significantly strengthening its balance sheet.
Cash Runway: The company ended Q1 with $64.5 million in cash, which is expected to fund operations into Q1 2023.
Clinical Progress: MT-401 began dosing in the safety lead-in portion of its Phase II AML trial, with plans to open the main trial in Q3 2021.
Manufacturing Improvements: Marker reported a 50% reduction in manufacturing time and major process simplifications, which are expected to lower costs and improve scalability.
Strong Early Data: MT-401 continues to show promising safety and efficacy signals in AML, with no major adverse events observed and favorable survival outcomes reported from academic studies.
Focus on Expansion: The company is preparing to open more clinical sites and is considering additional indications, though AML remains the primary focus.
